DOI: 10.12890/2026_005605
Unmasking cytomegalovirus colitis: a case of haemorrhagic colitis in a patient with chronic myeloid leukaemia on dasatinib
Authors
ctole@sbhny.org
Keywords
Chronic myelogenous leukaemia, haemorrhagic colitis, dasatinib, cytomegalovirus infectionAbstract
Background: Tyrosine kinase inhibitors (TKIs) are the first-line treatment for chronic myeloid leukaemia (CML) with BCR-ABL1 translocation. Dasatinib, a second-generation TKI, is associated with a wide range of adverse effects such as myelosuppression, pleural effusion, diarrhoea, and haemorrhagic colitis in up to 40% of patients. Additionally, its off-target immunomodulatory effects on natural killer cells and T lymphocytes may lead to the reactivation of latent infections, including cytomegalovirus (CMV), a known cause of colitis.
Case report: We present a case of CMV-associated haemorrhagic colitis in a 69-year-old woman with CML in complete remission, who was being treated with dasatinib. She was admitted to our hospital with a 1-month history of generalized weakness, light-headedness, and intermittent haematochezia. On presentation, she was hypotensive and tachycardic due to haemorrhagic shock. Urgent colonoscopy revealed multiple small ulcers and erosions in the rectum, sigmoid, and transverse colon with signs of active bleeding, which were managed with haemostatic clips. Rectal biopsy initially showed mild, non-specific chronic inflammation. Dasatinib was discontinued due to suspected drug-related colitis. However, post-discharge immunohistochemistry revealed localized CMV inclusions, prompting readmission and initiation of valganciclovir therapy.
Conclusion: This case highlights the importance of considering opportunistic infections such as CMV in CML patients receiving TKIs. Given the overlapping clinical and endoscopic features of CMV and dasatinib-induced colitis, histopathological evaluation is essential for accurate diagnosis and timely management.
References
- Yim E, Choi YG, Nam YJ, Lee J, Kim JA. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia. Korean J Intern Med 2018;33:446–448. doi: 10.3904/kjim.2015.325
- Torres HA, Chemaly RF. Viral infection or reactivation in patients during treatment with dasatinib: a call for screening? Leuk Lymphoma 2007;48:2308-2309. doi: 10.1080/10428190701760086
- Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–2541. doi: 10.1056/NEJMoa055229
- Yamauchi K, Inaba T, Colvin HS, Sakakihara I, Yamamoto K, Izumikawa K, et al. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scand J Gastroenterol 2022;57:449–456. doi: 10.1080/00365521.2021.2022190
- Chuang TM, Hsu CM, Liang PI, Hsiao HH. Cytomegalovirus colitis with presentation of hemorrhagic colitis in chronic myeloid leukemia during dasatinib therapy. J Formos Med Assoc 2021;120:1155-1157. doi: 10.1016/j.jfma.2020.10.009
- Yassin MA, Nashwan AJ, Soliman AT, Yousif A, Moustafa A, AlBattah A, et al. Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy. Clin Med Insights Case Rep 2015;8:77-81. doi: 10.4137/CCRep.S25327
- Choi JK, Cho SY, Choi SM, Kim GH, Lee SE, Lee S, et al. Cytomegalovirus colitis during dasatinib treatment for patients with hematologic malignancy: case series and literature review. Infect Chemother 2018;50:153–159. doi: 10.3947/ic.2018.50.2.153
- Quintás-Cardama A, Kantarjian H, Ravandi F, O’Brien S, Thomas D, Vidal-Senmache G, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115:2482–2490. doi: 10.1002/cncr.24257
- Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366–1377. doi: 10.1182/blood-2007-04-084814
- Shanshal M, Shakespeare A, Thirumala S, Fenton B, Quick DP. Dasatinib-induced T-cell-mediated colitis: a case report and review of the literature. Acta Haematol 2016;136:219–228. doi: 10.1159/000448983